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ABSTRACT
Dermatophyte onychomycosis is a common condition, particularly in the elderly and immunosuppressed. As these sections of
the population are set to increase, it is likely that the prevalence of dermatophytic nail infection will also increase. Advances in
antifungal therapy, with the introduction of newer and safer drugs such as terbinafine and itraconazole, have improved out-
comes significantly. However, around a quarter of patients will suffer reinfection or recurrence in the subsequent months. The
possible reasons for this are considered. Data from recently published studies have demonstrated an increased mycological
and clinical cure rate using a combination of topical and oral antifungal agents. This approach may be a cost-effective means
of improving outcomes for patients with more resistant nail disease.
INTRODUCTION
Onychomycosis is defined as a fungal infection of any part of the
nail u nit.
1 The disease predominantly  affects  the t oenails
2 and
accounts for almost 50% of all nail dystrophy.
3 Fungal nail infec-
tion may be caused by non-dermatophyte moulds (NDMs), yeasts
or  dermatophytes. NDMs  rarely  infect  the t oenails
4 and in
European studies account for around only 1.6–6% of cases of ony-
chomycosis.
5 More frequently they are found to co-exist with a
dermatophyte and are thus labelled as a ‘mixed’ infection.
6 Yeast
infections of the toenails are also rarely observed, usually being
associated with severe immunosuppression.
In clinical practice, 90% of toenail mycosis is caused by der-
matophyte infection,
7 where the condition is referred to as tinea
unguium.
8 In t he more t emperate climates  of Europe, t he
causative dermatophytes are almost exclusively Trichophyton spp;
Trichophyton rubrum, Trichophyton mentagrophytes (var. interdig-
itale) and, to a lesser extent, Epidermophyton floccosum .
3
Tinea unguium is almost invariably associated with skin inva-
sion.
9 Skin infection arises as fungal elements are disseminated by
infected individuals in areas such as swimming pools and com-
munal changing areas. The dermatophyte population in t hese
areas has been found to be high, particularly in the more humid,
tropical-type swimming pools.
1 . Fungal elements adhere to the
soles of the feet
11 and then invade the outer most layer of the epi-
dermis, t he s tratum corneum. Experimentally, penetration has
been shown to be enhanced in high humidity climates.
12  The num-
ber of patients  with skin infection who go on to develop nail
infection is unknown. In one study involving patients attending a
Japanese dermatology department, 59% of those diagnosed with
skin infection (tinea pedis) also had associated nail changes.
13 In
a similar type of study of European subjects, 23% of patients with
fungal skin infection of the foot also showed nail involvement.
14
Nail invasion by dermatophytes typically occurs through a dis-
tal-lateral subungual route. Subungual invasion causes nail-bed
inflammation with the production of subungual hyperkeratosis,
which leads to onycholysis. Superficial invasion of the dorsal sur-
face of the nail plate is less common, but is almost exclusive to
toenails.
15 As  the infection s preads, chronic nail infection may
lead to eventual total nail dystrophy.
PREVALENCE
The true prevalence of the disease is difficult to ascertain. Studies
have looked at specific occupational groups, geographical areas
and s elected age groups. Furthermore, s tudies  vary greatly
between t he diagnostic criteria and methodologies  employed.
Hay
16 has suggested the true prevalence lies somewhere between
3% and 22%. However, from most reported data it would appear
consistent that tinea unguium is a disease predominantly affect-
ing males
14 and has a prevalence that rises with age.
17
Fungal nail infection is rarely seen in children under the age
of t en. Studies  on y oung populations  suggest  a prevalence of 
0.19-2.1%.
18,19 The reason for this is unknown but it has been sug-
gested that a faster rate of nail growth in children and a lack of
cumulative trauma r enders the nail more r esistant to invading
fungi.
20 In adolescence the prevalence rises, steadily increasing to
a peak in those aged 55 and over.
2 As this section of the popula-
tion is likely to expand in numbers with increased longevity, it can
be assumed that the prevalence of onychomycosis will continue to
rise in parallel.
A number of risk factors have been suggested for the devel-





24,25 smoking and arterial disease
26
and psoriasis.
27 A review of the literature suggests that there is
conflict between authors in determining whether people with dia-
betes are more prone to onychomycosis. Romano et al ,
28 in a sur-
vey of 171 diabetic subjects and 276 controls concluded there was
no difference in infection rates.
However Gupta
29 examined 550 diabetic subjects and found
that diabetic individuals had a prevalence 2.77 times greater than
non-diabetics. Significant  risk factors  for  development  of ony-
chomycosis in people with diabetes included immunosuppressive
therapy, a family history and the presence of peripheral vascular
disease.
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Complications of chronic fungal infection
The nature of dermatomycosis is such that fungal skin infection
typically leads to fissuring of the epidermis. Dystrophic fungal nails
may harbour fungi and cause damage to adjacent soft tissues ren-
dering the foot susceptible to secondary invasion by pathogenic
bacteria such as Streptococci and Staphylococci. The link between
erysipelas and fungal foot infection has not been firmly established
but implied. A review of 30 patients with erysipelas of the leg and
foot found that 13 had concurrent fungal foot infection.
30 Dupuy in
a case-control study found that web space intertrigo was strongly
associated with a risk of developing erysipelas.
31 Tissue damage of
this extent can be a limb-threatening event for patients with risk
factors such as diabetes and peripheral ischaemia.
Quality of life
Not all patients with fungal foot infection seek treatment for the
condition, possibly due to r easons such as unawareness of the
condition or embarrassment. Maruyama and colleagues compared
a cohort of 41 individuals who were discovered by medical exam-
ination to have mycologically proven foot infection but not seek-
ing t reatment  with a group of diagnosed patients  who w ere
actively  seeking t reatment. The main difference between t he
groups was the level of symptoms suffered. Those seeking treat-
ment had significantly higher scores for erythema and itching.
32
Until recently, it was not known how nail disease impacted on
a patient’s life. In 1993, the first quality-of-life study was under-
taken examining s ufferers’ mental and general health u sing
adapted generic instruments. Lubeck
33 compared patients with ony-
chomycosis with controls and concluded that sufferers experienced
embarrassment and discomfort, thus reducing their quality of life.
Drake,
34 adapting t he Lubeck questionnaire, interviewed 2 58
patients by telephone and highlighted that three-quarters of suffer-
ers had difficulty with nail care, suffered embarrassment and nearly
half had associated pain. More recently a specific onychomycosis
measure (ODSQ) has been developed, which has shown greater
sensitivity than generic measures such as the SF-36,
35 but so far no
studies have been published documenting its use.
THERAPY
Traditionally the treatment of fungal nail infection has required
the use of a topical or systemic antifungal agent. In discussing the
effectiveness of various drugs it is important to highlight the wide
variation of reported cure rates between studies comparing anti-
fungal agents. The term ‘cure’ can be expressed as a clinical cure
in w hich v isible improvement  is  the main outcome measure,
mycological cure where there are no fungal elements identified
upon microscopy and culture or a combination of both (global
cure). Furthermore, populations  are s tudied u sing differing
methodologies and may have varying levels of nail disease.
Topical
Topical agents rely on sufficient penetration of the agent through
the affected nail plate. Owing to their limited penetration capac-
ity topical agents are only indicated for use in distal nail disease
when the nail matrix is spared.
Amorolfine is an antifungal of the morpholine class exhibiting
both fungistatic and fungicidal properties at low concentrations.
Its  main effect  is  against  dermatophytes  and s ome y easts, and
works by inhibiting the formation of ergosterol, a component of
the fungal cell membrane.
36 A study of its nail penetration abilities
was undertaken and it was concluded that amorolfine penetrates
through the nail within 24 hours following application, the degree
of penetration being influenced by the nails’ consistency and thick-
ness.
37 Available data suggest that topical amorolfine 5% (Loceryl
®
nail lacquer) applied to the toenails once weekly for six months
will lead to mycological and clinical cure rates of up to 66%.
38
Tioconazole is an imidazole derivative. Imidazoles have a sim-
ilar spectrum of activity to that of amorolfine. Their full mode of
action is not fully understood, however it is known that they work
by increasing fungal cell membrane permeability causing cellular
leakage and interference with cell division.
39 At lower concentra-
tions  imidazoles  have been s hown t o be primarily  fungistatic
rather than fungicidal,
40 which may explain their lower cure rates
compared with the more modern topical agents. Tioconazole is
available as a nail paint (Trosyl®) applied daily for six months.
Cure rates are around 22%.
41
Ciclopirox is a hydroxypyridone derivative, which differs from
other antifungal agents. It is thought to exert its effect by the
chelation of polyvalent cations rather than interfering with fungal
cell wall formation. It has been shown to be an effective topical
treatment for onychomycosis with a broad spectrum of activity
against dermatophytes, Candida albicans and some non-dermato-
phyte moulds.
42 Reported mycological cure r ates  have v aried
widely from study to study, ranging from 47% to 86%.
43 It is avail-
able as a nail lacquer in the US and some European countries, but
it is not currently licensed for use in the UK.
Systemic
Currently in the UK there are a number of systemic agents available for
the treatment of fungal toenail infection. Griseofulvin has been avail-
able for over 30 years. It is active against dermatophytes only as a
fungistatic, and as a result requires a long course of treatment (around
12-24 months). Comparisons with more modern systemic antifungal
agents have found it to have inferior cure rates of around 40%
44 and a
higher rate of side-effects when compared with newer agents.
45
Ketoconazole and fluconazole are members  of t he azole
group. Ketoconazole w as  the first  significant  broad-spectrum,
orally administered imidazole. Its fungistatic activity has limited
success on toenail mycosis.
46 Moreover, its use has declined owing
to its hepatotoxicity.
15,47 Both ketoconazole and fluconazole are not
currently licensed for fungal nail infection in the UK.
48
Itraconazole, a triazole, is a recent addition to the azole group
of drugs and is an effective treatment for fungal skin and nail
infection, persisting in these areas for some weeks after adminis-
tration.
49 It exerts its broad-spectrum effect on fungi by depleting
ergosterol, which is necessary for cell wall formation. Therapy for
nail infection is normally a 12-week course, 200mg daily. Cure
rates for onychomycosis are around 75%.
44 The drug has a slightly
superior effect over yeasts such as Candida albicans when com-
pared with terbinafine, as the latter has been found to be fungista-
tic r ather  than fungicidal against  this  particular  pathogen.
50
Itraconazole, however, has a higher number of drug interactions
with commonly used drugs such as oral hypoglycaemics, warfarin
and oral contraceptives, than terbinafine.
51
Terbinafine is an allylamine which like the azoles blocks fungal
cell wall development by inhibiting the formation of ergosterol. In
contrast to the azoles it acts at a more proximal point in the bio-
chemical pathway – inhibiting the enzyme squalene epoxidase. The
drug is rapidly absorbed and is well suited for the treatment of super-
ficial mycoses as it is rapidly distributed to the skin and sebum.
52
The drug is typically taken for 12 weeks (250mg daily) for con-
trol of toenail infection. In onychomycosis, studies have indicated a
mycological cure rate of around 75%. A meta-analysis undertaken
to evaluate and compare terbinafine with griseofulvin, itraconazole
and placebo in nail mycosis found that terbinafine had a significantOnychomycosis – a review of its presentation and treatment
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advantage over  these other  treatments  in t erms  of negative
microscopy and culture. Oral terbinafine is well tolerated,
53 with
minimal side-effects, the majority being transient in nature.
47 Costing
studies have been undertaken comparing the main systemic agents
and it  would appear  terbinafine is  the most  cost-effective.
47,54-56
The r esults from studies have established the superiority of this
drug over itraconazole in its mycological cure rate
57,58 and it is sug-
gested as the first-line oral therapy for tinea unguium.
44,48,59
REINFECTION AND RECURRENCE
Despite the seemingly improved cure rates over recent years with
new  and more effective t reatments  with around a quarter  of
patients, the problem persists or relapse occurs.
16 Often studies of
various interventions fail to follow up patients beyond a certain
time and so relapse rates may not be fully reported. An Icelandic
study followed up patients treated with oral therapy and found
that after five years only 46% of patients treated with terbinafine
remained disease free compared with just 13% of patients treated
with itraconazole.
58 Relapse can be categorised as  recurrence
(where the infection reappears after an absence of a year or more)
or reinfection (where the infection returns within a year). The lat-
ter typically suggests a poor response to antifungal therapy, thus
not achieving a mycological cure at the cessation of treatment.
Reasons for poor response are multifactorial. Scher & Baran
60
summarised the characteristics of the typical poor responder in a
recent paper (Table 1). Such patients may require longer courses
of therapy or a combination of treatments to eradicate successfully
long-standing fungal infections. Although resistance is mentioned
within the table there is currently little evidence to suggest that
drug resistance is a major problem in onychomycosis.
16
Recurrence usually arises a year or more after an infection has
been t reated and eradicated. Infection may  be r e-acquired
through exposure to fungal arthroconidia in old socks and shoes.
Where possible, discarding infected hosiery and footwear at the
time of mycological cure may reduce recurrence rate.
61 When this
is not possible, disinfection of the footwear should be carried out
with suitable antifungal powders or sprays.
A r ecent  study  tested t he efficacies  of v arious  disinfectant
agents  against  dermatophytes  that  could be u sed on personal
belongings to eradicate fungal elements.
62 Terbinafine 1% spray
was found to inactivate arthroconidia from five different strains of
Trichophyton (including T mentagrophytes and T rubrum ) As rein-
fection of the nails frequently follows from skin infection, it is
important to educate the patient with regard to skin care and the
regular  use of t opical agents  on s uspected s kin lesions. Some




Even with the latest developments of more modern topical and
systemic antifungal agents for onychomycosis, a relatively high
relapse rate still exists. In 1971, Medoff and co-workers first dis-
covered a synergistic effect in antifungal therapy when combining
two systemic antifungal agents.
64 Drug synergism can be defined
as a situation where a combination of two or more drugs has a
greater effect than the individual effects of each drug alone. The
potential advantages of combining antifungal agents include:
n Faster time to cure
n Increased curative effect
n Increased fungicidal activity
n Broader spectrum of activity
n Improved tolerability of the patient 
Recent studies have focused on the idea of combination ther-
apy for onychomycosis, combining an oral with a topical agent.
Olaffsson and colleagues
63 reviewed work reporting the effects of
various  combinations of oral agents  (griseofulvin, itraconazole
and terbinafine) with topical agents (amorolfine nail lacquer and
tioconazole paint). The greatest benefits have been reported by 12
weeks administration of oral terbinafine and 15 months of weekly
applications of amorolfine nail lacquer.
Mycological and clinical cure was observed in 72.3% of patients
using combination therapy compared with just 37.5% of those on 12
weeks of terbinafine alone.
65 Itraconazole (200mg once daily for 12
weeks) combined w ith once-daily  amorolfine nail lacquer  for  24
weeks versus itraconazole alone (200mg daily for 12 weeks) was also
found to have a superior mycological cure rate.
66 At week 24, 93.9%
of the patients on the combination therapy were mycologically cured
compared with just 68.8% of patients on itraconazole alone.
Lambert
67 conducted a cost-effective analysis using the data
from the two trials, and although the initial costs of prescribing
two agents for therapy may seem expensive, the two regimes were
found to be more cost-effective than monotherapy alone. As with
all new developments, more research is required to verify these
early reports and, in particular, longer term follow up of patients
would be beneficial to assess recurrence rates in these patients.
CONCLUSION
Onychomycosis, although a common condition, can be effectively
managed in most cases with minimal side-effects using modern
antifungal agents. Newer topical and systemic agents have shown
benefits over the more established drugs. Combination therapy in
initial studies has shown great promise in improving cure rates.
More t ime is  required w ith follow-up s tudies  to assess  relapse
rates in these patients.
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